Intratect (Human Normal Immunoglobulin)

Quick links

Choose a section

Quick links to important sections

Advertisements

Intratect (Human Normal Immunoglobulin)

Advertisements
Advertisements

Overview of Intratect (Human Normal Immunoglobulin)

Property Description
Active ingredient Human Normal Immunoglobulin
Form Solution for infusion
Pharmacological class Immune Globulin Intravenous (IVIg)
General purpose Immune replacement and modulation
Origin Pooled human blood plasma

What Type of Medicine is Intratect (Human Normal Immunoglobulin)?

Intratect (Human Normal Immunoglobulin) is a biological medicine classified as an Immune Globulin, or Intravenous Immunoglobulin (IVIg). This medication belongs to the anatomical therapeutic chemical (ATC) group J06BA02, which specifically designates normal human immunoglobulins for intravascular administration. As a solution for infusion, Intratect is a high-purity preparation, delivered exclusively via the intravenous route. Its classification confirms its role as an agent clinically recognized for its ability to stabilize or support the body's defensive systems in patients requiring immune support, distinct from other dosage forms like subcutaneous immunoglobulin.


Composition and Origin: Is Intratect a Blood Product?

Intratect is a plasma derivative; it is a purified blood product sourced from the pooled plasma of thousands of healthy human donors. Its active component, Human Normal Immunoglobulin, consists primarily of Immunoglobulin G (IgG) molecules, representing the full spectrum of IgG subclasses naturally found in the population. The pooling of plasma from many donors ensures the preparation contains a broad and diverse range of antibodies. This biological origin is critical, as the resulting product is not a single chemical entity but a complex, naturally occurring mixture intended to replenish or modulate the immune system.


General Purpose: How Does Intratect Support the Body?

The general purpose of Intratect is to provide essential support to the body's immune system by offering immediate passive immunity and immunomodulation. This medication is utilized as replacement therapy to restore abnormally low levels of functional antibodies in individuals who cannot produce adequate amounts themselves. For instance, in a typical use scenario concerning primary immunodeficiency, this medicine provides the necessary antibodies the patient cannot generate. IVIg is recognized as a standard treatment strategy that provides necessary antibodies for patients with certain primary immunodeficiencies. By supplying these protective proteins, Intratect helps to strengthen the body’s defenses and stabilize the recipient's overall immune responses.

Regulatory References

  1. EMA Scientific Guideline on Human Normal Immunoglobulin (IVIg)
  2. NIH/MedlinePlus Drug Information on Immune Globulin Intravenous (IVIG)
Advertisements

What side effects are possible with Intratect (Human Normal Immunoglobulin)?

Possible side effects and safety information

Intratect (Human Normal Immunoglobulin) is a plasma-derived medicine whose official safety profile is strictly defined by regulatory authorities, classifying documented adverse effects across various system-organ classes.


Official Classification of Adverse Reactions

Adverse reactions are categorized by frequency and the body system affected. Common effects (up to 1 in 10 patients) include headache, chills, nausea, fever (pyrexia), back pain, and arthralgia (joint pain). Uncommon effects (up to 1 in 100 patients) may involve hypersensitivity reactions, myalgia (muscle pain), and gastrointestinal issues like diarrhea.

Frequency Classification Key Adverse Reactions (System-Organ Class)
Rare (Up to 1 in 1,000) Sudden fall in blood pressure, Anaphylactic shock
Very Rare (Up to 1 in 10,000) Thromboembolic events (e.g., stroke, pulmonary embolism), Acute Renal Failure, Aseptic Meningitis Syndrome (AMS)
Not Known (Cannot be estimated) Transfusion-Related Acute Lung Injury (TRALI), Neutropenia

Contextual Safety Patterns and Contraindications

Adverse reactions may be more frequently observed in patients receiving IVIg for the first time, when switching between products, or when there is a long interval since the previous infusion. Reactions may also be related to the rate of infusion.

The medicine is contraindicated in individuals with a known hypersensitivity to human immunoglobulin and in patients with a selective IgA deficiency who have pre-formed anti-IgA antibodies.

Safety caution is advised for specific populations, including the elderly, obese patients, and individuals with pre-existing risk factors for thrombosis (such as diabetes or hypertension), due to the risk of serious vascular events. The medicine can also interfere with the effectiveness of certain live attenuated vaccines.

Advertisements

Overdose and Emergency Response

Overdose and when to seek help

Overdose with Intratect (Human Normal Immunoglobulin) is officially documented to result primarily from excessive volume or administration rate, leading to two main physiological manifestations: fluid overload (volume excess) and increased thickness of the blood (hyperviscosity). These documented presentations define the official overdose profile for this product.

This condition is considered potentially severe because the resulting fluid shifts and hyperviscosity carry the risk of serious complications, particularly the potential for acute renal failure and the worsening of pre-existing impaired heart function. The regulatory prescribing information identifies specific patient groups at higher risk for these severe outcomes, including children, elderly patients, and individuals with known impaired kidney function or impaired heart function.


Emergency Actions Mandated by Regulators

If a possible overdose is suspected, official regulatory guidance mandates immediate procedural action: a healthcare professional, such as your doctor or nurse, must be told immediately. This is required so the physician can promptly decide if the infusion should be stopped and if an alternative treatment should be administered. No specific pharmacological antidote is documented in the official labeling; management is supportive. To mitigate the risk of hyperviscosity, patients are also advised to maintain adequate fluid intake.

Advertisements

Therapeutic Uses of Intratect (Human Normal Immunoglobulin)

What Intratect (Human Normal Immunoglobulin) Treats: Main Uses and Benefits

Intratect is generally considered relevant for providing therapeutic support by addressing symptomatic clusters that arise from significant immune system compromise or dysfunction. The product category is applied across two major therapeutic domains: replacement therapy to help manage infection risk and immunomodulation for symptoms associated with certain autoimmune conditions. Its use across these domains is aligned with established clinical applications for human normal immunoglobulin.


Key Therapeutic Domains

This medicine is commonly used to help manage symptoms and provide immune support in conditions including Primary Immunodeficiency Syndromes (PIDs), Immune Thrombocytopenia (ITP), certain autoimmune neuropathies like Guillain-Barré Syndrome (GBS) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), and acute systemic inflammation like Kawasaki Disease.

For patients relying on this therapy, the goal is often long-term stability:

“The therapy is applied when the body needs supportive assistance in maintaining essential protective functions against recurrent illness or inflammation.”


Quick Fact: Symptomatic Support for Recurrent Infections

Quick Fact: Symptomatic Support for Recurrent Infections

In cases of antibody deficiency, Intratect is used to help reduce the frequency and severity of serious infectious episodes, which supports general well-being and lessens the symptom load associated with chronic illness. In autoimmune settings, it assists with maintaining functional stability by easing symptoms like muscle weakness or bleeding risk.

Regulatory References

  1. European Medicines Agency guideline on IVIg
Advertisements

Eligibility and Restrictions for Use

Intratect is approved for use in adults, children, and adolescents (0–18 years) under licensed indications for replacement therapy and immunomodulation. Eligibility is strictly defined by regulatory documents, which establish both absolute prohibitions and conditional requirements for use.


Contraindicated Populations

The medicine must not be used if a patient has:

  • Known allergy (hypersensitivity) to human immunoglobulin or any of the other ingredients.
  • Selective Immunoglobulin A (IgA) deficiency with antibodies against IgA in the blood, due to the high risk of a severe allergic reaction (anaphylaxis).

Condition-Based and Age-Related Restrictions

While generally approved for all ages, special care is required for certain populations to mitigate serious risks like thromboembolism (blood clots) and acute renal failure, as noted in the label warnings:

Special Caution Population Eligibility Constraint
Thrombotic Risk Patients with advanced age (over 65), hypertension, diabetes mellitus, a history of vascular disease, or obesity.
Renal Impairment Pre-existing renal insufficiency requires careful monitoring of kidney parameters and adequate hydration.
Reproductive Status Use during pregnancy or breastfeeding is permitted with caution based on clinical experience, though controlled safety trials are lacking.

Eligibility is conditional upon the patient's existing risk factors, and administration must be tailored (e.g., minimum infusion rate) in these high-risk groups.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information describes specific constraints regarding the co-administration of human normal immunoglobulin with other medicinal products, primarily focusing on vaccine effectiveness and co-administration safety.

Live Attenuated Virus Vaccines

  • Interacting Products: Measles, rubella, mumps, and chickenpox vaccines are specifically listed as interacting agents. The passive transfer of antibodies in the immunoglobulin preparation may temporarily impair the efficacy of these live attenuated virus vaccines.
  • Timing Restriction: Vaccination with these vaccines should be deferred for an interval of up to three months after the administration of Intratect. For the measles vaccine, the recommended deferral period may extend to up to one year to ensure an optimal immune response.

Other Medicines

  • Loop Diuretics: The concomitant use of loop diuretics and Intratect should be avoided. This restriction is documented in regulatory labeling to prevent potential complications.

Effects on Diagnostic Tests

  • The presence of various passively transferred antibodies in the recipient's blood following immunoglobulin infusion may lead to misleading positive results in serological tests. This temporary effect on blood tests should be considered during laboratory evaluations.
Advertisements

Mechanism of Action

️ How Intratect (Human Normal Immunoglobulin) Works

The mechanism of action for Intratect involves a dual strategy: immediate passive immune replacement and complex immune system modulation, both mediated by its diverse polyclonal Immunoglobulin G ( IgG) content.


Direct Antibody Replacement and Pathogen Neutralization

This domain addresses the use of IgG to restore humoral defense. The infused antibodies’ F( ab')2 regions directly bind and neutralize foreign molecular structures (antigens) and pathogenic self-directed autoantibodies. The process establishes immediate provision of IgG molecules capable of threat recognition, contributing to the establishment of passive systemic immunity against microbial threats.


Competitive Blockade of Fc-Receptors

This mechanism represents a key aspect of the immunomodulatory action. The IgG Fc region competitively saturates and blocks activating Fc-gamma receptors ( Fcgamma R) on effector cells like macrophages. This interference prevents pathological immune complexes from binding, which interrupts the downstream signaling that leads to the accelerated phagocytosis or clearance of self-cells.


Modulation of Cellular Homeostasis

Intratect influences the balance of the adaptive immune system by promoting the expansion of regulatory T cells ( T Reg) and shifting the overall cytokine profile toward an anti-inflammatory state. This cellular adjustment modulates the dynamics of the immune response and influences the overall physiological state toward reduced autoreactivity.

Advertisements

Dosage and Administration Information

Intratect must be administered strictly as an intravenous infusion (a 'drip' into a vein) by a healthcare professional. The dosage and the schedule are not fixed but are individualised based on the patient’s body weight and their specific clinical condition.

Administration Guidelines

Administration Scope Standard Requirement
Route Intravenous infusion.
Preparation Must be brought to room or body temperature before use. It must not be mixed with other medicinal products.
Age Group Dosage in children and adolescents (0-18 years) is not different from adults as posology is based on body weight and clinical outcome.

Procedural Conditions and Dosing Rules

The infusion process requires specific procedural steps to be followed:

  • Initial Rate: The infusion must begin at a slow rate (e.g., for the 50 g/l concentration, no more than 0.3 ml/kg/h for the first 30 minutes).
  • Rate Increase: If the infusion is well tolerated, the rate may be gradually increased up to a maximum (e.g., 1.9 ml/kg/h for the 50 g/l strength). For certain replacement therapy patients, the rate may be increased up to 8 ml/kg/h.
  • Dosing Rules: Dosing frequency depends on the condition. For replacement therapy, the maintenance dose is typically given every 3 to 4 weeks. Dosage is adjusted by the physician to achieve specific trough levels of IgG (Immunoglobulin G) in the blood.
  • Traceability: The name and batch number of the product must be recorded to ensure traceability.

These instructions define the standardized, professional protocol for using the medicine, ensuring its correct method of delivery and individualized dosing under medical supervision.

Advertisements

Recent Clinical Evidence

Research evidence / Overview of Studies for Intratect (Human Normal Immunoglobulin)


Evidence for Use in Primary Immunodeficiency Syndromes (PIDs)

Research exploring the use of this medicine for Primary Immunodeficiency Syndromes (PIDs) often includes non-randomized, open-label clinical trials. These studies were conducted to explore the administration of replacement antibodies in adult and pediatric populations. Researchers monitored outcomes related to systemic or functional imbalance, focusing on the annual frequency of serious infections and other acute relevant infections. Findings indicate patterns where the measured Immunoglobulin G (IgG) trough concentration was associated with the reported frequency of infections. Evidence is limited in certain areas, particularly in providing clear guidance on optimal dosing intervals for all patient groups.


Evidence for Use in Autoimmune Neuropathies: CIDP and GBS

Research examined the medicine's use in autoimmune neuropathies, including Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). Studies explored the treatment in adults using controlled trials, which measured outcomes reflecting daily functioning or activity level using specialized disability scales. Findings describe patterns observed in the studies where functional scale scores were measured as higher in the studied group compared to the placebo group. For Guillain-Barré Syndrome (GBS), comparative studies measured similar outcome patterns between the medicine and therapeutic plasma exchange (TPE) regarding functional disability.


Evidence for Use in Immune Thrombocytopenia (ITP) and Kawasaki Disease

Immune Thrombocytopenia (ITP)

This medicine was studied for Primary Immune Thrombocytopenia (ITP), a condition associated with episodes of low platelet counts. Research highlights changes measured during the study period, reporting patterns of increased measured platelet counts after administration. Data show patterns related to sustained changes being associated with long-term remission in pediatric populations, though results apply only to the populations studied.

Kawasaki Disease

Research examined the medicine's use in pediatric patients with acute Kawasaki Disease as part of a combination regimen. Data show patterns related to the timely administration of the combination regimen being associated with measurements of reduced occurrences of coronary artery abnormalities (CAAs).


Areas of Research Uncertainty and Study Gaps

A significant gap across multiple indications involves the biological mechanism by which these measured changes occur; research is ongoing to better understand this. For chronic conditions, follow-up durations were limited in many controlled trials, meaning long-term effects are not fully established. Comparative evidence is lacking for many subgroup findings, and data for certain patient groups remain insufficient to draw broad conclusions.

Key Studies & References

  1. SUMMARY OF PRODUCT CHARACTERISTICS: Intratect 100 g/l, solution for infusion
  2. Intravenous Immunoglobulin (IVIG, Bioven) Efficacy and Safety in Chronic Primary Immune Thrombocytopenia (ITP) in Adults (Trial Protocol)
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Intratect (Human Normal Immunoglobulin) (FAQ)


Q: Does Intratect help the body fight infections?

Official information indicates that the medicine contains Immunoglobulin G (IgG) with a broad range of antibodies against infectious agents. The purpose is to help restore low IgG levels to the normal range, a process associated with establishing passive systemic immunity to support the body’s defenses.


Q: Are there any specific activities or foods to avoid while taking Intratect?

Regulatory documents do not list any specific foods that must be avoided while receiving this treatment. However, the official product information states that patients who experience adverse reactions should wait for these effects to resolve before driving or operating machines, as the medicine may have a minor influence on these abilities.


Q: How long does the effect of Intratect usually last?

The duration of the effect is individualized and depends on the specific condition being managed. For patients receiving replacement therapy to correct an antibody deficiency, the dosage interval, once stable levels are reached, typically ranges from three to four weeks.


Q: How often is Intratect usually given?

The frequency of administration is managed by a healthcare professional and is individualized based on the patient's condition. For chronic replacement therapy, it is often given every three to four weeks. For treating certain inflammatory disorders, such as Guillain-Barré syndrome, administration may occur over a short course, often five days.


Q: What kind of monitoring is done during an Intratect treatment?

Patients are closely observed for any symptoms throughout and immediately after the infusion. Regulatory documents also advise that for all patients, kidney function should be monitored by checking urine output and serum creatinine levels. Healthcare professionals also measure IgG trough levels (the lowest antibody concentration) as part of the process to maintain the appropriate dosage.


Q: How quickly does Intratect start working for immune deficiency?

The medicine is immediately and completely available in the recipient’s circulation after the intravenous infusion. While the antibodies are provided right away, achieving stable, therapeutic antibody levels for chronic immune deficiency typically takes three to six months after beginning regular therapy.


Q: Can Intratect interact with common over-the-counter medications?

Official regulatory documents specifically mention interactions with live attenuated virus vaccines (like for measles, mumps, and rubella) and the co-administration of loop diuretics, which should be avoided. Official product information is focused on known interactions, and does not provide general statements regarding all common over-the-counter medicines.


Q: Does Intratect help with autoimmune diseases?

The medicine is licensed for the treatment of specific inflammatory and autoimmune-related conditions. These licensed indications include Primary Immune Thrombocytopenia (ITP), Guillain-Barré Syndrome (GBS), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), and Kawasaki disease.


Q: What is the typical duration of treatment with Intratect for chronic conditions?

For chronic conditions like Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), the treatment effect is evaluated after each cycle. If the treatment achieves the desired response, official product information states that long-term treatment may be a continued option.


Q: What are the official eligibility criteria for Intratect treatment?

Eligibility is based on the licensed therapeutic indications established by regulatory authorities. This includes patients requiring replacement therapy due to an antibody deficiency and patients needing immunomodulation for specific inflammatory conditions (e.g., ITP, GBS, CIDP, Kawasaki disease).


Q: Can Intratect be used alongside blood thinners, based on official information?

Official information does not list blood thinners (anticoagulants) as a direct interaction. However, regulatory warnings describe caution for patients with pre-existing risk factors for thromboembolic events (blood clots). In these at-risk patients, the infusion must be given at the minimum practicable rate.


Q: How is Intratect different from other IVIG treatments?

Intratect is a specific Intravenous Immunoglobulin (IVIg) product. Its official composition is documented, noting that it is stabilized with glycine and does not contain excipients like sucrose, maltose, or glucose. These compositional details distinguish it from other products in the IVIg class.


Q: Is it normal to feel tired after receiving an Intratect infusion?

Official side effect lists for human normal immunoglobulin products include symptoms like fatigue and malaise (a general feeling of discomfort or illness). These are typically reported as being transient and mild. Any persistent or severe symptoms are generally information for the supervising clinician.


Q: What is the difference between Intratect and a vaccine?

Intratect provides passive immunity by directly supplying the body with ready-made antibodies (IgG). A vaccine works differently by stimulating the body to actively produce its own antibodies. Official documents note that the passive transfer of antibodies from Intratect may temporarily affect the effectiveness of live attenuated vaccines.


Q: What are the risks of using Intratect if I have kidney issues?

Patients who have pre-existing renal insufficiency (kidney issues) are identified in official warnings as being at increased risk for a very rare, but serious side effect called acute renal failure. For these patients, careful monitoring of kidney parameters and adequate hydration, along with using the minimum practicable infusion rate, are described as necessary precautions.


Q: Does Intratect contain sugars or salt that I should be aware of?

The product is stabilized with the excipient glycine and is officially described as being sugar-free; it does not contain sucrose, maltose, or glucose. It does contain a small, varying amount of sodium (salt) depending on the vial size.


Q: Is Intratect a treatment that cures a disease, or does it manage symptoms?

Official product information describes this medicine as either a replacement therapy to restore low antibody levels or as an immunomodulation therapy to influence the immune response. In many chronic conditions, if the medicine is effective, long-term administration is used to manage the condition.


Q: Can Intratect be used in patients with heart problems?

Caution is advised for patients who have pre-existing risk factors for blood clots, which includes certain cardiovascular issues like hypertension (high blood pressure) and a history of vascular disease. Myocardial infarction (heart attack) is listed as a very rare potential side effect in official documents.


Q: Does Intratect interfere with the effectiveness of common prescription drugs?

Official documents describe specific interactions with live attenuated virus vaccines and advise against the co-administration of loop diuretics. Information on specific prescription drugs should be obtained from the healthcare provider.


Q: Does Intratect contain a specific type of antibody?

The active substance is Human Normal Immunoglobulin, which primarily consists of Immunoglobulin G (IgG) molecules. The IgG content is distributed across all four naturally occurring IgG subclasses (IgG1, IgG2, IgG3, and IgG4) in proportions that closely resemble those found in normal human plasma.


Q: Is Intratect used for conditions outside of immune system problems?

The licensed uses of the medicine fall under either replacement therapy for low antibody levels or immunomodulation for specific inflammatory conditions, such as certain autoimmune neuropathies. These uses are related to stabilizing or supporting the body's defensive systems.

Advertisements

How should Intratect (Human Normal Immunoglobulin) be stored and disposed of?

How to Store and Dispose of Intratect (Human Normal Immunoglobulin)

Intratect must be stored under specific environmental constraints as defined by regulatory labeling. The product must be kept at a temperature not above 25 C and must not be frozen. To protect the solution from light, the vial should remain in the outer carton until administration. Solutions must be inspected for cloudiness or deposits before use and should be brought to room or body temperature prior to infusion. While its shelf-life is three years, the medicine may be stored at room temperature (below 25 C) for up to nine months after removal from refrigeration, but must be discarded if unused after this period. After first opening, immediate use is recommended. The medicine must be kept out of the sight and reach of children. Unused product and waste material must be disposed of in accordance with local requirements.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Intratect (Human Normal Immunoglobulin) found in:

A-Z Index: